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CHAPTER I:
INTRODUCTION
Rlbl ImmunoChem Research, Inc. competes in the highly competitive 
biopharmaceutical segment of the biotechnology industry. Devoted to 
improving human health, the Company is racing to develop new-generatlon 
health care products that could improve existing malignant and 
infectious disease therapy. Beyond improving existing therapy, the 
Company is also researching methods of using its proprietary technology 
to prevent certain malignant and infectious disease ailments.
Ribi ImmunoChem Research, Inc. "is engaged in the research, 
development, production, and marketing of biopharmaceutical agents which 
can be used as adjuvants"! Known to boost immune system response to 
infection, the Company's adjuvants are gaining considerable recognition. 
By researching adjuvant products that are more effective, less toxic, 
and void of serious side effects, the Company has earned a reputation as 
a world leader in molecular immunotherapy research.
Ribi ImmunoChem Research, Inc. pursues corporate strategy aimed at 
perfecting its technology, and moving new-generatlon health care 
products to market as quickly as possible. Managed by a team of 
competent business executives who direct the research and production 
efforts of skilled research scientists, the Company hopes to soon market 
its first adjuvant product intended for human use.
 ̂Ribi ImmunoChem Research. Inc., SEC Form 10-K (Annual Report). 
31 December 1986, p.l.
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This paper will analyze the Company's corporate strategy.
Presented in a case format, the initial chapters will first describe 
Ribi ImmunoChem Research, Inc.'s historical and current company 
operations. Following chapters will examine its markets, and the 
industry’s major competitors. The final chapter will analyze Ribi 
ImmunoChem*s strategy in light of Company capability, competition, and 
industry trends. Recommendations will also be included, suggesting 
methods of strengthening strategy.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
CHAPTER II:
RIBI IMMUNOCHEM RESEARCH, INC.; COMPANY BACKGROUND
A. Dp . Rlbl, Scientist and Pounder. After serving thirty years with 
the National Institute for Allergy and Disease Control, in 1981 Dr.
Edgar Ribi retired. Anxious to continue adjuvant research, he forged 
ahead to found the company that bears his name.
Besides founding Ribi ImmunoChem Research, Inc., Dr. Ribi can be 
credited for numerous microbiology research advances. In the early 
1960*s, he invented the Ribi Cell Fractionator, a tool with numerous 
invaluable research and production functions. In 1981, he and his 
colleagues discovered a reproducible method for detoxifying endotoxin 
while preserving the compound's potent adjuvant properties. The 
adjuvants extracted from endotoxin became the key stimulating 
Ingredients for the Company's anti-tumor products. Finally, until his 
unfortunate death in 1986, Dr. Ribi asserted the importance of adjuvants 
in future health care through publication of 185 reports, and countless 
presentations at national and international science conferences. Many 
adjuvant experts considered Dr Rlbl the world's leader in adjuvant 
research.
B. IncoPiK>ratlon. Ribi ImmunoChem Research, Inc. was incorporated on 
January 9, 1981. Dr. Ribi filed the Company's Articles of Incorporation 
in Delaware and located the business in Hamilton, Montana. Selecting to 
file articles of incorporation in Delaware is common among U.S. 
corporations because "Delaware imposes the lowest annual franchise tax
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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nationally, treats corporations liberally, and Is strategically located 
on the East C o a s t .
Ribi ImmunoChem Research, Inc. is a public corporation capitalized 
exclusively through issuance of common stock. Because Ribi and other 
public corporations involve the use and custody of stockholder funds and 
securities, they are subject to federal and state regulation.
1. Incorporation— Regulation. The Securities Exchange Acts of 1933 and 
1934, established the Securities and Exchange Commission to regulate 
securities markets and trading. In accordance with their regulatory 
responsibility, the SEC requires Ribi ImmunoChem officers file quarterly 
and annual performance reports describing the Company's operating and 
financial condition.
State corporate regulation laws vary from state to state, but 
generally speaking, they all define the powers granted corporations 
Additionally through Blue Sky Law provisions, regulation protects 
prospective stockholders from misleading information intended to attract 
investment through promises of the "blue sky."
Usually state governments assume regulatory responsibility by 
enforcing "state corporation codes." Although Ribi ImmunoChem 
Research, Inc. is a Montana-based foreign corporation (they were 
incorporated out-of-state), they are subject to the same Montana codes 
as domestic corporations. Similar to the SEC, Montana law requires Ribi 
ImmunoChem file annual performance reports of their financial and
2 Marvin Kristein. Corporation Finance. (New York: Barnes and Noble 
Books: 1975), pp. 12-13.
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operating condition.
C. Adjuvants. From research pioneered by Dr. William Coley at the turn 
of the 2 0th century, a relationship was discovered between bacterial 
Infection and malignant tumor regression. Dr. Coley believed that a 
cancer patient could be injected with certain bacterium to stimulate an
immune response. Often he found the response powerful enough to not
only kill the bacterium intruder, but also the patient's malignant tumor 
cells. Unfortunately, too often the bacterium was toxic, ruling the
practice inappropriate for human health care.
Determined that "Dr. Coley's toxins" could be made safe without 
destroying their therapeutical properties. Dr. Ribi spent most of thirty 
years researching methods to eliminate the toxicity of endotoxin, one of 
Coley's toxins. In the early 1960's he advanced his research methods 
with the invention of the Ribi Cell Fractionator, "a machine that breaks 
bacterial cells apart, allowing the protoplasm (which contains many 
contaminants) to be removed from the cell wall, from which a variety of 
adjuvants can then be extracted."3
Adjuvants are bacterial-borne chemicals, capable of stimulating a 
general immune system response. They can be applied alone or in 
combination with substances (antigens) specifically targeted for 
particular ailments. They have long been perceived by Dr. Ribi and his 
Company associates as safe and effective ways for treating and 
preventing malignant and infectious disease.
3 "Ribi ImmunoChem Research, Inc.," Research; Ideas for Today's 
Investors. January. 1988. p.2.
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Rlbl ImmunoChem Research. Inc.’s products are formulated using four 
primary adjuvants: TDM (trehalose dimycolate), CWS (cell wall skeleton). 
MPL^ (monophosphoryl lipid A), and PA-PE (propionibacterium acnes- 
pyridine extract). Mixed together in varying combinations, the 
adjuvants have yielded three principle products (DETOX*, OVAMID*, and 
RIBIGEN®).
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
CHAPTER III:
RIBI IMMUNOCHEM RESEARCH, INC.; CURRENT COMPANY OPERATIONS
A The Mission. Ribi ImmunoChem Research. Inc. is "engaged in the 
research, development, production and marketing of biopharmaceutical 
products, which can be used as adjuvants."*
According to Nils Ribi, the Company's Chairman of the Board, "our 
corporate mission is to become a fully-integrated pharmaceutical 
company, with primary focus on the development and application of 
adjuvants for human health care."5
B. Marketing/Distribution Strategy. Since incorporation, Ribi 
ImmunoChem Research, Inc. fostered a corporate marketing strategy to 
"avoid licensing away its proprietary products and technology in return 
for some credibility and minor royalties,"® The strategy proved 
valuable— the Company controls all of its products and technology amidst 
considerable industry interest in Ribi ImmunoChem products and 
processes.
In seven years of operation, the Company has identified numerous 
new adjuvant applications. Responding to the growth, in July 1987, 
Company officials launched a refined corporate marketing strategy. They 
examined the relationship between two market entry barriers (the
* Rlbl ImmunoChem Research, Inc., SEC Form 10-K. Annual Report, 
31 December 1966, p.l.
® Personal interview with Nils Ribi, Chairman of the Board, Ribi 
ImmunoChem Research, Inc., Hamilton, NT, 13 November 1987.
® Ribi ImmunoChem Research, Inc., 1987 Annual Report, p.2.
7
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research and development time and expense, and Ribi's access to 
particular markets), and devised strategy that would generate maximum 
product returns.
To date, Rlbl ImmunoChem Research. Inc. follows the following three 
marketing strategies outlined In the Company's 1987 Annual Report;
— > In areas where Rlbl ImmunoChem has already established 
leadership (such as DETOX^ and OVAMID^), product development should be 
short. Accordingly, the Company plans to develop and market the product 
itself when the physician target audience is small and market size 
substantial. This should allow the Company to minimize marketing 
expense and maximize potential profits.
— > Where the Company's products dovetail with another major 
company's research program, Rlbl ImmunoChem plans to seek partnerships 
to develop the products. Once completed, the partner would assume the 
marketing responsibility. This arrangement should provide license fees, 
research funding, and royalties as the revenue sources.
— > When a major health care company dominates a particular market 
area and Ribi ImmunoChem's adjuvants enhance the other company's 
products (as in the area of vaccines). Ribi ImmunoChem intends to 
directly license products with accompanying license fees and royalties 
as revenue sources?
C. The Products. Ribi Immunochem scientists research adjuvant 
applications "designed to stimulate an Immune response in man and
Ibid, p.10.
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animals in order to prevent and treat malignant and infectious 
disease."6 The applications are being developed;
— > to provide human cancer therapy,
— > to boost the activities of vaccines to prevent and treat human 
infectious conditions,
— > and to prevent and treat human infectious conditions through 
general immune system stimulation.
In February, 1987, Nils Ribi was optimistic that his adjuvants 
could include a fourth application--prevention of cancer. He was 
quoted, "right now the approach we're all taking is treating cancer.
Here with this vaccine (using Ribi ImmunoChem adjuvants) lies the 
possibility that you can truly have a preventative against cancer.”® 
Additionally, to a lesser extent. Ribi ImmunoChem is developing 
adjuvants for veterinary uses in preventing and treating both malignant 
and Infectious diseases.
1. The Products— DBTOX*. One year after incorporation, Ribi 
scientists had developed DETOX™, the Company's first adjuvant anti­
tumor human health care product. DETOX™ can be delivered alone to 
stimulate a localized Immune response or in combination with a "cancer 
vaccine." Depending on the method of delivery, the product is ideally 
suited for therapeutical use in combatting malignant melanoma, Kaposi's
® Ribi Immunochem Research, Inc.. SEC Form 10-K (Annual Report>. 
31 December 1986, p.l.
® Greg Lakes, "Keeping Cancer at Bay," Missoulian. 11 February 
1987, pp.1-2.
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sarcoma, lung cancer, pancreatic cancer, leukemia, genital and common 
warts.
To date, malignant melanoma appears to be the most promising 
DETOX^ application. "In October 1987, Ribi ImmunoChem Research, Inc. 
signed a $1 million, five-year research agreement with the University of 
Southern California to sponsor Dr. Malcolm Mitchell's work with melanoma 
cancer vaccines in return for commercial rights to certain products."^® 
"Initially, the work will focus on the use of a vaccine in cancer 
treatment, but eventually it will include study of cancer prevention."11 
In Phase I testing, Dr. Mitchell has found that by combining 
DETOX* with existing melanoma vaccines and injecting patients:
— > ten out of seventeen patients with spreading melanoma showed 
signs that stimulation of their immune system to battle 
melanoma had been achieved;
— > eight of those patients showed measurable reduction in their 
tumor sizes— two experienced complete tumor regression, three 
experienced reduction of tumor size by at least 50%, and three 
experienced minor tumor regression.
— > the results were better than those achieved using conventional 
chemotherapy, and without significant side effects.1%
Having satisfied precllnical and Phase I human clinical tests.
10 Rlbl Immunochem Research. Inc., 1987 Annual Report, p.5.
"Rlbl Signs Pact with USC Cancer Research," Missoulian. 15 
October 1987, p.1 2 .
Rlbl Immunochem Research. Inc., 1987 Annual Report, pp.5-6.
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DETOX* Is currently undergoing Phase II trials. Pending more melanoma 
patient tests, by the end of 1988 DETOX^ should enter Phase III trials. 
Finally, as a genital and common wart therapeutic, DETOX* has entered 
Phase I of human clinical testing.
2. The Products— OVAMID*. OVAMID* is the Company's second anti­
cancer agent. Developed in 1983, OVAMID* might provide relief from 
ovarian, cervical, colorectal and bladder cancers. Unlike the cancers 
targeted for DETOX* treatment, cancers targeted for OVAMID* treatment 
are not solid masses: rather, they spread within human cavities. Direct 
intralesional injection of any type is thus impossible. Accordingly, 
OVAMID* has been developed as a soluble product which can be used to 
bathe the tumor cells within body cavities.
OVAMID* is currently undergoing Phase I trials of ovarian cancer 
patients to evaluate the product's safety. "Preliminary reports 
indicate that treatment with OVAMID* has been tolerated by most 
patients and no adverse side effects have been seen. Reports also 
indicate that the therapy has at least halted tumor growth in some 
patients, indicating that OVAMID*'s activity may stabilize the 
disease."13
3. Tb# Products— MPL*. Monophosphoryl lipid A (MPL*) is one of Ribi 
Immunochem's three proprietary adjuvants. Although the adjuvant is a 
key DETOX* and OVAMID* ingredient, alone MPL* Is also a powerful 
stimulator of non-specific resistance to infection. In particular, the
13 Ibid.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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adjuvant might prove effective protection against infections including: 
malaria. AIDS, hepatitis A and B, certain forms of septicemia, and other 
infections plaguing patients whose immune system is compromised 
(chemotherapy/burn/radiation patients, and the elderly).
In 1987, "Ribi Immunochem Research, Inc. signed an agreement with 
the U.S. Army Medical Research and Development Command for the 
evaluation and testing of Ribi products MPL* in a malaria vaccine.
Ribi's product MPL^ is being considered a way of making the vaccine 
more potent."14
In March 1987, Ribi ImmunoChem Research, Inc. "signed an evaluation 
and option agreement with Baxter Healthcare Corporation to study MPL^ 
in a limited area of infectious disease prevention."!® Under the terms 
of the agreement, Ribi will receive monthly payments from Baxter during 
the option period and will provide the material MPL* to Baxter for the 
studies.
MPL* "is expected to enter Phase I clinical trials in 1988 as a 
malaria vaccine adjuvant and also for use prior to high-risk surgery as 
a stimulator of non-specific resistance to opportunistic infections."1®
4. The Products— RIBIGEN*. In 1983, Ribi ImmunoChem Research, Inc. 
received full governmental approval to distribute RIBIGEN®, a highly 
effective commercial anti-tumor veterinary product. RIBIGEN® was
14 "Rlbl To Test Products for Malaria Vaccine," Missoulian, 22 
October 1987, p.15.
1® Ribi Immunochem Research, Inc., 1987 Annual Report, p.4.
1® Ribi Immunochem Research, Inc., 1987 Annual Report. Company Profile
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
13
Introduced to treat eye cancer In cattle and sarcoid tumors in horses. 
"Cure rates of 90% in horses and 66% in cattle, regardless of the tumor 
size treated"17 created widespread attention.
Initial consumer reaction to RIBIGEN® was encouraging. Test 
marketing of the product in 1983 resulted in $30,000 sales. In 1984, 
sales of the product increased 449% over 1983 sales. 1985 sales 
remained constant, and Ribi ImmunoChem Research, Inc. negotiated an 
exclusive marketing agreement with Fort Dodge Laboratories, a major 
worldwide pharmaceutical distributor. The agreement did not increase 
sales however--1986 RIBIGEN® sales dropped dramatically (96%), a problem 
created by Fort Dodge's failure to honor product purchasing agreements. 
Seeking a network of distributors, Ribi ImmunoChem successfully doubled 
RIBIGEN® 1986 sales in their 1987 marketing effort.
5. The Products— Research Products. Ribi Immunochem Research, Inc. 
"markets a line of 49 research products worldwide to industrial, 
governmental, and academic laboratories."^® "Many researchers have 
described the Company's microbial adjuvants (research products) as the 
best available, both for increased efficacy and reduced side effects."1®
With the exception of investment income, Ribi's research products 
generate most of the Company's revenues. In fact, the past two years 
(1986, 1987) research products have generated approximately 30% of total 
Company revenues. (See Table 2).
17 Ribi Immunochem Research, Inc., 1983 Annual Renort. p.2 .
18 Ribi Immunochem Research. Inc. , 1987 Annual Report, Company Profile
19 Ribi Immunochem Research, Inc. , 1988 Annual Renort. p. 1 0 .
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D. Federal Regulation. Depending whether Ribi’s products are intended 
for human or veterinary use, different federal agencies regulate the 
products' manufacturing, testing, and marketing phases of product 
development. For human biopharmaceutical products, the Federal Drug 
Administration monitors precllnical studies, filing applications, human 
clinical trials, and product license application approval. For 
veterinary products, the U.S. Department of Agriculture monitors product 
development. If either human or veterinary products are intended for 
foreign distribution, often foreign regulating agency procedures must be 
satisfied.
"The process of seeking and obtaining FDA approval of a new product 
takes a number of years and often involves substantial expenditures "20 
Nils Ribi, Ribi Immunochem Chairman of the Board, recently stated. "We 
estimate it takes at least eight years for our human health care 
products to move from the laboratory to the consumers."2 *
Prior to approval of a Product License Application (PLA), a series 
of tests must successfully be completed. First, precllnical product 
tests must be conducted in the laboratory and on animals. The tests 
results are submitted to the FDA with an Investigational New Drug 
application (IND). If the IND is approved, human trials may commence.
Three phases of human clinical trials are required. Phase I trials 
test maximum tolerated dosage and possible side effects on human
20 Ribi Immunochem Research. Inc., SEC Form 10-K (Annual Report). 
31 December 1986, p.11.
21 Opening address by Nils Ribi for dedication of Ribi ImmunoChem 
Research, Inc. new research facilities, Hamilton. MT, 19 March 1988.
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volunteers (cancer patients in the case of anti-tumor agents). Phase II 
trials examine the most effective dosages and schedules of 
administration for specific ailments common to groups of patients.
Phase III trials Involve wide-scale studies to examine patient group 
response rates to the biologies. Once all phases of trials are 
successfully complete, a Product License Application may be submitted to 
the FDA. If the PLA Is approved, the product may then be commercially 
distributed.
USDA testing of veterinary products usually Is less time consuming 
and less expensive than FDA testing. Accordingly, "potentially faster 
product approval through the USDA makes the animal health Industry
highly competitive."22
On June 22, 1987, the FDA changed their strict drug approval 
policies. Prior to the June decision, drug manufacturers "could make 
experimental drugs available free of charge, on a compassionate basis 
for gravely ill patients."23 with the policy change, under certain 
conditions drug manufacturers can charge patients a fee for recovering 
the drug's manufacturing costs. The change Increases opportunities for 
Rlbl Immunochem Research, Inc. and other drug research firms to expand 
their patient test base, while recovering some of the expensive research 
costs.
E. Patents and Protection. Ribi ImmunoChem Research, Inc. "maintains a
Ribi Immunochem Research. Inc., SEC Form 10-K (Annual Report).
31 December 1986, p.12.
22 Marilyn Chase. "FDA Rule Changes May Rush New Drugs to Very Sick 
Patients," Wall Street Journal. 5 October 1987, pp.l and 22.
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Strong patent position (with 13 U.S. and 94 foreign patents issued or 
allowed, and 6 U.S. and 54 foreign patents pending) for the manufacture, 
composition and use of its products and t e c h n o l o g y . " 2 4
To maintain a competitive position within the industry, biotech 
firms must develop patentable products and/or processes. Ideally, 
patents protect firms against piracy, and generate compensation for 
exchanges of products or processes. In practice however, "there is no 
assurance that others may not independently develop similar technology 
or that secrecy will not be breached."25
To reduce information piracy and improve licensing revenues. "Ribi 
Immunochem Research. Inc. maintains an active trademark protection 
program in the U.S and those countries where it expects to market its 
products."26 Additionally, all employees are sworn (through employment 
agreements) to not disclose proprietary information for two years 
following their separation from the Company.
P. Staffing. According to Nils Ribi. "since incorporation in 1981,
Ribi Immunochem Research, Inc.'s staff has grown from four to fifty 
people."27 Of the fifty, more than half are directly involved in 
research and development.
24 Ribi Immunochem Research, Inc., 1987 Annual Report. Company Profile
25 Rlbl Immunochem Research. Inc., SEC Form 10-K (Annual Report).
31 December 1986, p.13.
26 Ribi Immunochem Research, Inc., SEC Form 10-K (Annual Report).
31 December 1986, p.13.
2"̂  Nils Rlbl dedication address of new facility, Hamilton, MT.
19 March 1988.
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Nils Rlbi has long stressed the importance of quality research 
conducted by leading scientists to assure a competitive position within 
the biotechnology industry. He has also supported the Importance of 
staffing leading business officials experienced in pharmaceutical 
marketing. Accordingly, Ribi ImmunoChem Research, Inc. has employed 
research scientists (many Ph.D.s) and experienced business professionals 
to develop the products and bring them to market. Figure 1 on the 
following page depicts the Company's organizational structure.
One of the strengths of Ribi ImmunoChem's leaders has been their 
ability to recognize their own limitations. Beginning with Dr. Edgar 
Ribi and later his son Nils, the two leaders never risked Company 
success by involving themselves in operations where they were not 
qualified. If they were not expertly experienced in specific facets of 
the Company's operations, they employed someone who was.
In 1987, Nils Ribi "urged the board to find a new president for 
Ribi ImmunoChem Research. Inc. when he was named chairman following the 
death of his father.'*28 Speaking in his own behalf. Nils Rlbi said, "I 
think I am a very good start-up company person, a very good organizer, a 
good systems man. I can put together a company In the early stages and 
build it. But this gets very complex. I don't want to let an ego get 
in the way of the success of the Company."28
Supporting Mr. Rlbi's recommendation, the Company's board embarked 
on a lengthy search for a new president and chief executive officer. In
28 "Rlbi President Fits With Plans for Growth Era," Missoullan. 5 
July 1987, p.B-1.
28 Ibid.
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July, 1987, they announced their pleasure to employ Mr. Robert Ivy, an 
experienced (30 years) pharmaceutical and marketing manager with 
companies Including G.D. Searle, Scherlng A.G., and Revlon Health Care.
The last four of the thirty years, Mr. Ivy headed a company involved In 
cancer-related contract research.
In March 1988, Nils Rlbi and Bob Ivy announced "the Company's plans 
to triple Its size to about 150 employees In the next five years."30 As 
a means to generate a good pool of local Job applicants, the Company 
leaders also announced that they would provide more than $60,000 to fund 
graduate research at the University of Montana In the 1988-89 academic 
year. Additionally, "the University will appoint selected Rlbi 
scientists to lecture In microbiology, mlcrochemlstry, and chemistry 
courses at Rlbi's expense."31
G. Facilities. Prior to Incorporation. Dr. Edgar Ribi sketched plans 
for his company while continuing adjuvant research In a renovated garage 
In Hamilton, Montana. As the needs of production, research, and 
development grew, the Company (over the last seven years) expanded its 
facilities in phases. To date, Rlbi ImmunoChem Research, Inc. occupies 
40,000 square feet of high-technology facilities located on 35 acres in 
Hamilton.
A recently completed $2.7 million expansion project ($1.6 million 
for construction, $1.1 million for new equipment) doubles Ribi
3® Theresa Johnson. "Ribi to Help Fund Graduate Research at UM, 
Missoullan. 20 March 1988, pp.1-2.
31 Ibid.
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ImmunoChem'9 production area and triples laboratory space for research 
and development. "The added space will allow the company to 
significantly increase production of Its proprietary anti-tumor agents 
DETOX^ and OVAMID^ in order to maintain adequate supplies for expanded 
clinical trials."32 Additionally, the added space will be used for 
production of antigens for use in cancer vaccines.
H. Financial Condition. Company success hinges on moving products 
successfully through clinical testing. To date, one veterinary product 
(RIBIGEN®) has received approval for commercial distribution. DETOX*, 
a potentially more profitable human health care product, has been 
undergoing testing since 1983. Although clinical approval of the 
product may never come. Ribi ImmunoChem Research, Inc. must generate 
capital to fund continue research and development.
The Company generates capital through operating, investing, and 
financing activities. Investment income earns the majority of the 
Company's operating capital, followed by product sales, contracted 
services, and licensing (see Figure 2). Liquidated investment 
securities have provided in excess of $3 million dollars in 1986 and 
1987, while stock proceeds have generated $26,181 for the same period.
Although the Company has not generated sufficient revenues to earn 
profits yet, Ribi ImmunoChem Research, Inc. has expanded laboratory 
facilities and acquired new laboratory equipment without incurring long­
term debt. Ribi ImmunoChem officers expect not to be profitable until
Ribi ImmunoChem Research, Inc., 1987 Annual Report, p.10.
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the Company's expanded research and development effort moves the first 
human health care product to market.
(The following discussion refers to Rlbi ImmunoChem Research,
Inc.'s financial statements included in the Appendix).
1. The Income Statements (Statements of Operations). Ribi ImmunoChem 
Research, Inc. has not been profitable. Every year except 1986, 
management has recorded losses. 1986 would also have also been 
unprofitable, however life insurance proceeds (from Edgar Rlbi's policy) 
were significant enough to generate a Company profit.
Salaries and research and development expenses comprised eighty- 
eight percent of the Company's 1987 expenditures, compared to eighty- 
seven percent in 1986 and seventy-three percent in 1985. Salaries is 
the Company's single most expensive item, accounting for forty-four 
percent of 1987's expenses.
Product sales have grown steadily since 1981, however investment 
income has generated the most Company revenue. Total revenues have not 
been sufficient to produce annual profits— in 1987, total revenues were 
fifty-nine percent of total expenses. Figure 2 charts revenue trends of 
the three most significant Income sources. As a supplement. Table 2 
details the revenue breakdown of all income sources for the three-year 
period 1985 through 1987.
2 The Balance Sheets. Most of Rlbi ImmunoChem's total assets are 
marketable security investments, purchased with proceeds from public
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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Stock sales In prior Issuances. In 1986 and 1987. investment securities 
had represented over two-thirds of the Company's total assets, an 
unusually high percentage.
Company assets have grown rapidly since 1981. With first year 
total assets of $1,984,422, the Company's assets have grown to 
$15,586,206. Although the assets have grown, the stockholders equity 
per share has fallen from $2.09 in 1981 to $1.74 in 1987 (see Table 1).
1987 plant expansion and equipment purchases have been paid with
cash Using 1985 cash flows contributed by common stock proceeds of $11 
million, and liquidated investment securities of over $3 million in 1987 
and 1986, the Company has generated adequate cash flows to cover 
expansion and operations. Table 4 traces Ribi ImmunoChem Research.
Inc.'s historical cash flows from 1985 through 1987.
Table 4 also includes annual (pro forma) cash flow projections. 
According to the table, if:
— > Ribi ImmunoChem triples its labor force over the next five 
years as announced.
— > product sales do not improve (assuming sales will not improve 
significantly until a new product is approved for commercial 
distribution).
— > stock issuances yield the same proceeds as 1987.
-> and the Company is forced to continue the recent trend of
liquidating investment securities,
Ribi ImmunoChem Research. Inc. will run out of cash (and investment 
securities) by 1991. However, if the Company chose to not triple the 
labor force in the next five years, and sales and stock proceeds
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remained the same, the Company would only need to liquidate half its 
investment securities to generate a positive cash flow in 1991 (see 
Table 6 ). Ribi ImmunoChem has avoided debt, and is backed by 
considerable short-term investments. Accordingly, its liquidity 
position has been strong. Table 1 tracks the company's liquidity 
position through current ratio analysis. Although the table does not 
predict the Company's ability to pay off future debt, liquidity would 
drop if (as predicted) investment securities were sold to fund future 
operations.
3. Shareholders' Equity. At the close of 1987, Company records listed 
approximately 1,444 shareholders. Of the shareholders. Executive Life 
Insurance is one of the largest, owning over 600,000 shares. Ribi 
officers, employees, and other persons providing important Company 
services share in Rlbi ImmunoChem Research, Inc. ownership through a 
stock grant program and a stock option plan. Approximately eleven 
percent of Company stock is held in this manner.
Currently the Company's Board of Directors, has authorized Ribi 
ImmunoChem management to sell 20 million common shares (at $.001 par). 
Slightly more than 8.5 million shares have been issued. The gap between 
the authorized celling and number of shares issued provides considerable 
opportunity for investors to purchase Ribi stock.
Table 3 compares important shareholder Information. First, Ribi 
ImmunoChem has not paid dividends to shareholders. Second, the number 
of shareholders has grown steadily since the first public offering.
Third, each year (but one) the shareholders have incurred losses per
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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Share. Finally, the Company's stock price is volatile, attracting only 
the most speculative investor According to April 1987 Standard and 
Poor’s PTC Stock Reports (vol.53. no 41. sec 30). Rlbi ImmunoChem*s 
beta coefficient is 2 .8 6 .
Figure 2 
Ribi ImmunoChem Research, Inc.
Major Revenues
0.8 -4
0 .4  -4
0.1
1985 198619821981
p r o d u c t  s d t e s c n t r c t  s r v c s T n v s t
source; Ribi ImmunoChem Research. Inc. income statements: 1981— 1987
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Ratios/Years:
Profitability:
ROA
ROE
Table 1
Rlbi ImmunoChem Research, Inc.
Financial Ratios
1987 1986 1985 1984 1983 1982 1981
(.070) .003 (.030) (.052) (.058) (.073) (.081)
(.070) .003 (.030) (.053) (.059) (.074) (.107)
Liquidity:
Current ratio 19.73 114.96 95.09 24.29 60.89 32.08 32.02
Indebtedness:
Debt/equity .039 .008 .009 .030 .013 .026 .324
Shareholders
Equity:
Equity/share 1.74 1.87 1.86 .78 62 1.49 2.09
source: calculations based on extrapolation of financial figures
provided in Rlbi ImmunoChem Research, Inc.'s financial 
statements (1981-87)
Table 2
Rlbi ImmunoChem Research, Inc. 
Detailed Revenue Breakdown
Year Ended December 31 1987 1986 1985
Amount % Amount % Amount %
Research products $ 450,863 29 $ 455,276 28 $ 182,259 19
License & option fees 92,903 6 12,000 1
Investment Income 866,548 55 1,106,708 69 595,956 61
Contract services 124,136 8 25,046 2 1,225
Animal prods. (RIBIGEN®) 12,403 1 5,732 - 160,000 16
Laboratory Animals 12,507 1 13,494 1 28,346 3
Other 4.807 __2 4,743 — 186 ‘tm
Total Revenues $1,564,167 100 $1,610,999 100 $979,972 100
source: Rlbi ImmunoChem Research, Inc., 1987 Annual Report
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Table 3
Rlbi ImmunoChem Research, Inc. 
Shareholder Data
Year ended Dec,,31: 87 86 85 84 83 82 81
Book value NA 1.87 1.86 .78 .62 .66 . 29Stock Prices:
Hig 11 3/8 11 1/2 10 6 8 1/8 5 1/4 2 1/2Low 3 5 4 3 3 1/8 1 1/8 1 1/8
Beta 2.86
Equity/share 1 .74 1.87 1.86 .78 .62 1.49 2.09Earnings/share ( . 13) .01 (.06) (.08 (.07) ( .1 1 ) ( .2 2 )
Ave.number of
shares outstanding
(millions) 8.6 8.6 7.5 3.4 3.1 2.6 .72
Dividends paid 0 0 0 0 0 0 0
source: Rlbi ImmunoChem Research, Inc. financial statements; Standard
and Poor's OTC Stock Reports (vol. 53, no. 41, sec . 30). 10 April 1987.
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Table!
RIBI IWJNOCHW RESEARCH. INC 
Pro Forma Cash Flows 
(Thousands)
1985 1986 1987 1988 1989 1990 1991
Cash Flows from Operating Activities:
Net Income (Loss) (479) 55 (1.086) (1,790) (2.496) (3.198) (3.902)
Oepreciation/Amort ization 146 135 147 300 300 300 300
Accounts Receivable (33) 9 (4) 0 0 0 0
Accrued Interest Receivable (255) (402) 472 0 0 0 0
Inventories 41 (34) 17 0 0 0 0
Other Current Assets (22) (52) 22 0 0 0 0
Acooints Pebble (21) (95) 324 0 0 0 0
Accrued Expenses 11 62 146 0 0 0 0
Deferred Income 6 (6) 0 0 0 0
Net Cash Flows from Operating Activities (612) (316) 32 (1.490) (2.196) (2,898) (3,602)
Cash Flows from Investing Activities:
Capital Expenditures (161) (204) (2,175) 0 0 0 0
Payments for Other Assets (102) (49) (96) 0 0 0 0
Change in Investment Securities (10.694) 2,714 425 1000 2200 2855 1500
Net Cash Flows from Inw ting Activities (10,957) 2,461 (1,846) 1,000 2,200 2,855 1,500
Cash Flows from Financing Activities:
Proceeds from Issuance of Stock 11,115 19 7 7 7 7 7
Net Increase (Decrease in Cash) 
Cash-aaglmlng of Year 
Cash—  End of Year
(454)
727
2,164
273
(1,807)
2,437
(483)
630
11
147
(36)
158
(2.095)
122
$273 $2,437 $830 $147 $158 $122 ($1,973)
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CHAPTER IV:
THE MARKETS
Ribi ImmunoChem Research. Inc. is engaged In the research and 
development, production, and marketing of adjuvant products and 
technology. The Company believes that by developing safe, affordable, 
and effective adjuvant products. It will replace conventional cancer and 
Infectious disease health care methods which are too often unsafe 
(toxic), disabling, or not affordable.
In its corporate strategy, the Company has identified two human 
health care markets to aggressively pursue; infectious disease and 
cancer. Both are perceived to offer extreme profit potential, and both 
are prime adjuvant targets. Nils Ribi. Board Chair, speculated In 
October 1987 that the cancer vaccine market could be $500 million. 
Infectious diseases, on the other hand, "could be as high as $3 
billion."33 Supporting Rlbi's estimate, a recent report published by 
the 1987 Biotechnology Data Group estimated the market for new 
infectious disease adjuvant vaccines could "reach $1-2 billion 
worldwide."34
Generally speaking, it is impractical to approximate (in dollars) 
the total size of Infectious disease and cancer markets. Since adjuvant 
technology for the proposed Company applications is still undergoing 
testing and development, specifying costs associated with dosage.
33 Personal interview with Nils Ribi, Board Chair, Ribi ImmunoChem 
Research. Inc.. Hamilton, Montana. 23 October 1987.
34 1987 Biotechnology Data Group. "Drug Delivery/Formulation," Issues 
and Commentary Reports. (Cambridge, Massachusetts, 1987), pp.3-5.
28
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product effectiveness, and delivery methods, etc. is difficult.
However, in order to gain a sense of the market magnitude for adjuvant 
applications, Chris Dyzynski (Ribi ImmunoChem's Marketing Manager) has 
ventured potential market guesses for the following infectious disease 
and cancer applications.
A. Infectious Diseases. Ribi ImmunoChem scientists are researching two 
infectious disease applications: developing their adjuvants for 
combination with new generation vaccines, and using their adjuvants to 
enhance high-risk patients' non-specific resistance to a variety of 
infections. The potential market for each application is tremendous.
1. Infectious Diseases— Vaccines. Vaccines using Company adjuvants 
could create tremendous sales potential. To date, Ribi ImmunoChem is 
collaborating with select researchers in an effort to improve or 
discover new vaccines that could treat and prevent malaria, hepatitis, 
AIDS, tetanus, and genital warts.
It is estimated that 78 million people suffer from malaria each 
year. Most of the victims are from third world nations, often too poor 
to afford vaccine treatment that is usually not effective anyway 
Accordingly, Ribi ImmunoChem Research, Inc. is currently providing the 
U.S. Army Medical Research and Development Command Company adjuvants for 
evaluation and testing in new, more effective, affordable vaccines. At 
an estimated per treatment cost of $.30, the annual malaria vaccine 
market could exceed $23 million.
Hepatitis is a viral infection of the liver caused by contact with
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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contaminated blood. According to a 1987 Wall Street Journal article, 
some 300,000 people get hepatitis each year in the U.S.; there are more 
than 250 mi il ion carriers world-wide and two million associated deaths 
annually."35 The market for hepatitis vaccine and tests during 1988 has 
been estimated at $20 0 million.
Depending on the source, national estimates of the number of actual 
AIDS cases and number of people exposed to the AIDS virus vary. Ribi 
ImmunoChem estimates 42,000 people suffered from AIDS in 1986, while 
three million people were likely exposed to the virus. Estimating 
treatment of $2.0 0 per patient exposed to the virus yields a potential 
AIDS market of $6 million. Further, until an AIDS treatment is 
developed, the incidence of the disease will grow exponentially in 
future years, rapidly expanding the market potential.
Tetanus effects over seven million victims nationally each year.
Ribi ImmunoChem Research, Inc. estimates that a new vaccine treatment 
(which Includes Company adjuvants) could create a market in excess of 
two million dollars each year.
Finally, "genital warts is believed to be the fastest spreading 
sexually transmitted disease in the United States, infecting an 
estimated one million persons annually."3® According to Hr. Dyzynski's 
treatment estimates ($75.00 per case), the infliction could create a 
potential DETOX* annual market of $75 million.
3® William Bulkeley, "Biogen Gets Broad Patent on Antigens For 
Hepatitis B Used By Other Firms," Wall Street Journal. 4 December 1987.
35 Rlbi ImmunoChem Research, Inc., 1987 Annual Report, p.8 .
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2. Infectious diseases— Non-specific Resistance and Ianune System
Compromised Patients. Ribi ImmunoChem's scientists are exploring other 
infectious disease adjuvant applications. They are evaluating adjuvant 
applications MPL^ that could assist high-risk patients with fending off 
infection. In particular, the scientists are examining the ability of 
the Company’s adjuvants to stimulate non-specific resistance to 
Infection in pre-operative patients, and in patients whose immune system 
is compromised.
Ribi ImmunoChem Research. Inc.'s marketing department has 
estimated that over eight million patients admitted to U.S. hospitals 
each year for surgery are prone to infection. The chance that Rlbi's 
adjuvants could prevent pre-operative infections might create a market 
of over $800 million annually.
If adjuvant applications are effectual in preventing infection 
amongst immune compromised patients (the elderly, or 
burn/radiation/chemo-therapy patients), the potential market is also 
staggering. In total, patients whose immune system is compromised could 
create an annual market in excess of $10 0 million.
Septicemia is a form of blood poisoning often acquired through 
patient exposure to hospital-borne (gram negative) bacteria. According 
to Ribi ImmunoChem Research Inc.'s 1986 Annual Report, "in the United 
States, more than 200.000 people annually develop septicemia in the 
hospital, and about half die regardless of therapy. The number of 
persons worldwide considered at risk for hospital-acquired infections 
has been estimated as high as a half-billion."3? If the estimated
37 Rlbi ImmunoChem Research. Inc., 1986 Annual Report, p.8 .
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treatment cost per case Is $500 (based on Company estimates), the
national septicemia market could be as high as $ 1 0 0 million.
B Human Cancer Applications. Cancer is a terrible threat to human 
health. The American Institute for Cancer Research specified, "In 1987, 
approximately 1,000,000 Americans will develop cancer. Every 65 
seconds, someone dies of cancer in America, and this year almost 500,000 
people will die of the disease. One out of every five deaths is from
cancer, the second leading cause of death in this country."^®
Certain human cancer forms are best suited for Ribi ImmunoChem 
adjuvant treatment. Each form creates a unique market. Following are 
the primary DETOX^ cancer markets the Company explores: malignant 
melanoma, lung cancer, leukemia, and pancreatic cancer. Additionally, 
potential OVAMID^ market applications include: superficial bladder 
cancer, colorectal cancer, and ovarian cancer.
1. Human Cancer Applications— DBTOX*. Malignant melanoma is usually 
characterized as a dark-pigmented skin tumor. "22 , 0 0 0 cases were 
reported in 1985 that resulted in approximately 7,400 deaths 
nationwide."39 Treatment of every reported case could yield a potential 
market of $6 6 million (based on an estimated $3000 cost per treatment).
Lung cancer effected 150,000 U.S. people last year. Assuming a 
level annual trend of case reports, a total market for this form of
3® American Institute for Cancer Research, Dietary Guidelines To Reduce 
Cancer Risk. (Washington, D.C.: Government Printing Office, 1987), p.2
39 Rlbi ImmunoChem Research, Inc., 1986 Annual Report, p.6 .
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cancer could exceed $400 million.
Leukemia is a disease involving the uncontrollable increase of 
leukocytes (white blood cells). According to Ribi market research,
"24.000 new cases are reported each year, and 16,000 deaths annually. 
According to Company treatment estimates, the annual leukemia market 
could equal $72 million.
"Pancreatic cancer has a high mortality rate because it is 
difficult to detect and has often spread to other organs before it is 
diagnosed. 25,000 new cases were reported in 1 9 8 4 . Accordingly,
Ribi ImmunoChem Research, Inc. estimates the potential market is $75 
million.
2. Human Cancer Applications— OVAMID*. The markets created by the 
other common forms of cancer targeted for OVAMID* treatment are also 
staggering. According to Rlbi's market research, potential markets for 
colorectal cancer could exceed $400 million, bladder cancer $100 
million, and ovarian cancer $50 million.
3. Human Cancer Applications— Strategic Available Markets. Although 
potential total cancer markets can be estimated, the market share Rlbi 
ImmunoChem Research, Inc. can capture is considerably less. Two factors 
shrink the Company's potential markets. First, often the treatment is 
administered in unison with other agents. In those cases where a 
vaccine is formulated using other agents. Ribi ImmunoChem Research, Inc.
40 Ibid.
41 Ibid.
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would only have right to revenues equaling the proportion of Company 
adjuvant products used. Secondly, Ribi ImmunoChem cannot expect to 
supply all of the needed therapeutics or preventatives. Limited 
physical production constraints will permit only predictable levels of 
production.
Accordingly, Ribi ImmunoChem Research. Inc. has estimated 
"strategic available markets" that the Company could capture annualIv. 
DETOX* cancer applications could capture 40% of the U.S. market ($200 
million). For genital warts, on the other hand, DETOX* could be 
applied to ten or twenty percent of U.S. cases ($10— 20 million).
OVAMID* has been targeted to capture five to fifteen percent of U.S. 
markets, or $15 million.
C. Animal Cancer Applications. Ribi ImmunoChem Research. Inc. is now 
primarily concerned with exploring human health markets. Initially, 
however, the firm was incorporated to "engage in the research, 
development, production and marketing of biomedical agents, which are 
designed to activate the human or animal immune system in an effort to 
combat diseases.
Animal health care is no longer the Company's primary market 
interest. According to Nils Ribi. "although we are phasing out animal 
health care products because they are not as profitable as the human 
health care products, we will not ignore animal application
Ribi ImmunoChem Research, Inc.. 1981 Annual Report, p.l
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opportunities discovered through human application research "*3
D. Research Products. Internationally, scientists seek Rlbi's 
adjuvants for research. The Company has Introduced their adjuvants as a 
ready-to-use "Ribi Adjuvant System." "RAS provides researchers with a 
convenient and highly effective adjuvant delivery system for vaccine 
testing In comparison to the previous research adjuvants."44
The research market supplements Rlbi revenue. Many industrial, 
academic, and governmental researchers consider Rlbi's adjuvants the 
best available. Marketing 50 adjuvants for research, 1986 and 1987 
research product sales comprised near 30% of total Company revenues.
(Table 2 displays a comparison of the Company's revenues from 1985 
through 1987).
43 Personal interview with Nils Ribi. Board Chair, Ribi ImmunoChem 
Research, Inc., Hamilton, MT, 23 October 1987.
44 Rlbi ImmunoChem Research, Inc., 1986 Annual Report, p.10.
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CHAPTER V:
INDUSTRY’S MAJOR COMPETITORS
A. Competition. Competition in the human blopharmaceutical Industry Is 
Intense. Scientists worldwide are racing to discover new generation 
vaccines plus more effective, non-toxic, and cheaper cancer and 
infectious disease treatments. They are driven by dreams of success and 
tremendous profits.
The industry is made up of competitors of various size and 
therapeutical approach. From private to public, international to local, 
worldwide interest in human health care attracts diverse competitors. 
Generally, the more notable competitors include: private research (large 
pharmaceutical companies, smaller biotechnology companies, private 
academic institutions); public research (hospitals, public academic 
institutions), government research (foreign and U.S.), and more 
commonly, collaboration between two or more competitors. Often the 
collaborations link capital with opportunity. Accordingly, the most 
small biotech firm could prove most competitive with financial backing 
from a heavily capitalized source.
According to Ribi, it is not necessarily financial strength, 
research facility size, or manpower that determine the level of industry 
competition. Rather, it is research experience— patentable research 
experience that produces non toxic, effective, and affordable products. 
Exploiting the Company's research strength. Nils Ribi described the 
Company's competitive strategy, "we intend to stay a step ahead of our 
competitors, and maintain our leadership position by continuing quality
36
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research and development of new adjuvants and applications for 
adjuvants."45
Nils Ribi contends that one measure of research experience is to 
examine a firm's scientific publications and presentations; the other is 
to note the number of patents that have been awarded.
Ribi ImmunoChem Research. Inc. maintains two bibliographies of 
published Company research and presentations. One bibliography (the 
Company's) documents 50 research publications and thirteen national and 
International presentations completed between 1982 and 1987; the other 
(Edgar Rlbi's) lists 185 research publications completed between 1948 
and 1985. The majority of the publications and presentations were 
either written or presented by Edgar Ribi. Often he co-authored the 
publications with other Company, national, or international research 
scientists.
Although Rlbi ImmunoChem scientists have published numerous 
research articles, Nils Ribi advised that the extent of publication has 
not weakened the Company's competitive stance. Mr. Rlbi remarked that 
by patenting new adjuvant applications or technology before publishing, 
the Company is protected by law from piracy.
Ribi ImmunoChem is also in a strong patent position. According to 
the Company's 1987 Annual Report. "13 U.S. and 94 foreign patents have 
been issued or allowed, with six U.S. and 54 foreign patent applications 
pending).”4®
45 Personal interview with Nils Ribi, Chairman of the Board, Ribi 
ImmunoChem Research, Inc., Hamilton. NT, 13 November 1987.
4® Ribi ImmunoChem Research, Inc., 1987 Annual Report. Company Profile.
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B. Industry Segmenta. The therapeutical approaches to providing relief 
from or prevention of cancer have created industry segments.
Immunotherapy, chemotherapy, radiation therapy, and surgery are the most 
common therapies today. Each has inherent limitations, some more severe 
than others. The latter three approaches "usually have serious side 
effects and leave the body defenseless against a recurrence of the 
disease."47 Traditional methods of immunotherapy, on the other hand, 
experience limited success.
Because current approaches are not effective, produce undesirable 
side effects, or are too toxic, many biotechnology companies are 
exploring new immunotherapeutical cancer treatments and vaccines to 
complement current approaches. "Such immunotherapy, as it's called, 
would complement the standard therapies: surgery, chemicals (or 
chemotherapy) and radiation."48 Research and testing of molecularly 
and genetically engineered adjuvant technologies are drawing 
considerable attention. According to the 1987 Biotechnology Data Group,
"a renewed interest in vaccine development has been inspired by the 
advent of new biosynthesis and molecular engineering technologies which 
offer a new range of potentially safe and effective products."49 {Table 
5 identifies major biotechnology competitors by their applications, and 
an estimated market share position they may control).
47 Ribi ImmunoChem Research, Inc., Research: Ideas for Today's 
Investors. January 1988, p.2.
4® Jerry Bishop. "Successes in Lung Cancer Vaccine Trials Raise Hope 
for Future of Immunotherapy," Wall Street Journal, (eastern edition),
16 September 1987, p.37.
49 1987 Biotechnology Data Group, "Drug Delivery/Formulation," Issues 
and Commentary Reports. September 1987, p.3.
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Ribi obtains their adjuvants from molecular engineering. Three of 
the Company's proprietary adjuvants are extracted from endotoxin, a 
highly toxic bacterium According to Table 5, Ribi ImmunoChem Research, 
Inc.'s cancer and infectious disease approaches are unique, creating 
opportunity for tremendous earnings.
C. Limitations to Industry Growth. The human blopharmaceutical 
industry can be "characterized as an emerging industry with multiple 
technological frontiers. Although regarded as a promising 'industry of 
the future,' its potential is uncertain and growth could occur in many 
directions."
The industry grows slowly. It is regulated by a complex 
intertwining of constraints: innovation, liability issues, and cost.
1. Innovation constraints. Innovation presents a continual industry 
challenge. The constant search for new ideas is challenged by 
Innovative ability, quality research, specialized high-tech equipment, 
capital, "and to some degree, on how much more scientists are able to 
learn about the elaborate workings of the immune system."31 According 
to a 1906 business and medicine report, "before the biotech boom can 
explode into vaccines, it must wait on the development of adjuvants. 
Progress toward developing more effective adjuvants, however, has been
33 Arthur Thompson and A.J. Strickland. Strategic Management: Concents 
and Cases. (Texas: Business Publications, 1984), p.102.
31 Delthia Ricks, "Vaccine Offers Hope in Melanoma Treatment," Los 
Angeles Times. 2 August 1907, Section II, p.3.
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9lOW”®2
Brainstorming and collaboration are methods of encouraging 
Innovation. Counter to historical industry trends, biotechnology 
companies, governmental agencies, and higher education institutions are 
sharing Information. Their research, and In some cases, capital are 
shared as they cooperatively develop new Ideas, technology and products. 
The 1987 Biotechnology Data Group report Justified recent Industry-wide 
collaborations, "these barriers to entry (Innovation constraints, 
liability issues, and cost) will necessitate collaborations between 
small companies and market leaders to bring new technologies to market, 
and support the costs of vaccine development and commercialization."®^
Rlbi ImmunoChem Research, Inc. actively seeks partners to help 
speed the Company's products to market. According to a 1987 trade 
Journal. "Rlbl is collaborating with about 20 other biotechnology 
companies. Typically, the collaborators team up to test a new Ribl 
adjuvant with synthetic vaccines produced by the other company."®* 
Recently, a licensing agreement between a moderate size 
biotechnology firm and a major pharmaceutical company have paid off.
Chiron (biotech firm) licensed their molecular technology to Merck and 
Company. Together they produced a new genetically engineered hepatitis 
B vaccine which received federal application approval In 1987. "Since
®2 Arthur Rlausner, "Booster Shots," In Vivo: The Business and Medicine 
Report. November/December 1986, Number 19. pp.21-22.
53 1987 Biotechnology Data Group, "Drug Delivery/Formulation." Issues 
and Commentary Reports. (Cambridge, Massachusetts: 1987), p.2.
®* Ricki Lewis. "Helping the Body Fight Cancer,” High Technology 
Magazine. January 1987. p.l.
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approval a year and a half ago, the vaccine has generated U.S. sales of 
$70 m i l l i o n , "55 according to Carolyn Patrick, Chiron Marketing 
Representative. (Ms. Patrick also stressed that Smith, Kline, and 
French have recently begun marketing a similar hepatitis B vaccine in 
Europe).
U.S. companies are not the only collaborators. Capital rich 
foreign companies have recently entered into agreements with domestic 
firms, the industry leaders. Promises of venture capital and/or royalty 
payments have prompted several American biotech companies to cooperate.
The exchange assists U.S. firms with delayed commercial payoffs and 
funds continued research.
Particularly. Japan has begun acquiring U.S. biotechnology secrets 
through licensing agreements. According to a recent Wall Street Journal 
article, "Suntory (Japanese firm) has aggressively been acquiring U.S. 
technology. They engage in Joint research with Rockefeller University 
on brain function and seeking drugs for the ills. They have also 
licensed from Biogen (U.S. firm) the right to produce a natural cancer 
fighter called tumor necrosis factor. Finally, they are looking for a 
broad partnership with a U.S. (biotechnology) company."®®
2. Liability Ismues. Litigation, damage awards, and liability costs 
are crippling the industry and forcing customers to pay Inflated health 
care prices. Until litigation relieves the industry of partial
®5 Telephone interview with Carolyn Patrick. Chiron Marketing 
Representative, 10 February 1988.
®® "Gene Squad; Japanese Target Another Industry in which the U.S. 
Holds a Lead." Wall Street Journal. 17 December 1987, p.18.
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liability responsibility, the industry's Increasing price trend Is not 
expected to change.
Before a human health care product is granted application approval. 
Federal Drug Administration requires it successfully pass four testing 
phases. The four phases of precllnlcal and clinical testing determine 
the product's safety, dosage, and effectiveness. Although commercially 
available vaccines are thoroughly tested and their applications 
federally approved, very Infrequently treatment using the product proves 
threatening/fatal.
Hampered by increased liability expenses and reduced profits, 
pharmaceutical corporations have been dropping from the industry. The 
1987 Biotechnology Data Group reported, "approximately 3 million doses 
of vaccines are administered on a yearly basis in the United States.
The number of vaccine-related injuries averages 75 cases per year. The 
resulting litigation, damage awards, and liability costs associated with 
this low incidence of adverse reactions has forced several companies out 
of the traditional vaccine b u s i n e s s . "57 (pigure 3 on the following page 
illustrates the 1985 human vaccine market share position of the four 
major U.S. pharmaceutical corporations).
The industry has been forced to dramatically increase product 
prices to cover inflated insurance costs. For example, "the price of 
DTP vaccine has Increased from $.37 per dose in 1982 to $11.22 per dose;
57 1987 Biotechnology Data Group, "Drugs DelIvery/FormulâtIon," Issues 
and Commentary Reports. (Cambridge, Massachusetts: 1987), p.4.
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Figure 3
1985 Human Vaccine Market Share»
Loboratoriea (8.0% )
Connaught Lobs. (14 .0% )
Ladarle Lab#. (18 .0% )
Marck &  Co.. Inc. (GO.
Source: In Vivo estimates
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insurance costs may comprise 70% of the price."5* Additional evidence 
from the 1986 Business and Medicine Report suggests, "that over $2 
billion in liability suits have induced Lederle to raise its price from 
seven dollars to over sixty dollars for a whooping cough vaccination."®^
3. Cost and Profitability. Tremendous research and development costs 
typify the industry. Sophisticated equipment, adequate facilities, 
quality scientists, and competent business executives are available at 
premium prices. Operating and administrative expenses are predictable; 
often income is not. Further, FDA product testing delays sales at least 
three years, but usually twice that long.
Survival in today's highly competitive biotechnology industry 
depends on maintaining a positive cash flow until products receive 
federal application approval. At a minimum, a company should expect 
delayed sales by three years for human health care products. Adequate 
capitalization, positive investment returns, loans, venture capital, 
contracted research, grants, licensing, and other collaborations are 
necessary to fend off bankruptcy if a firm lacks sales to support 
operating costs.
Eventual FDA approval (if granted) to market a cancer or infectious 
disease product typically escalates a firm's profitability 
substantially. During the I980's. drug companies annual profits grew
58 1987 Biotechnology Data Group. "Drug Delivery/Formulation.” Issues 
and Commentary Reports. (Cambridge, Massachusetts: 1987), p.4.
Arthur Klausner. "Booster Shots," In Vivo: The Business and Medicine 
Report. November/December 1986, No.19. p.21.
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twelve to fifteen percent. Before the October *87 stock market crash, 
the companies' third quarter net incomes had increased seventeen 
percent.GO
D. Industry Trends. At best, cancer therapy trends are sketchy. To 
date, cancer therapy has been limited to chemotherapy, radiation 
therapy, surgery, and traditional methods of immunotherapy. None of the 
therapies is totally safe nor do they always produce desired results. 
According to a Science News report, "survivors of childhood cancer have 
an increased risk of developing bone cancer later in life, primarily 
because of the use of radiation therapy and chemotherapy against the 
original cancer."Gl Additionally, a 1984 U.S. News and World Report 
describing interferon treatment, the only biological compound licensed 
for cancer treatment stated, "the experience with Interferon has been 
disappointing. The antiviral agent is found to help in some cancers 
Including Kaposi's sarcoma, but showed little effect against the major 
cancers— colon, breast, and lung."G2
Adjuvant cancer therapy may someday rule other therapies obsolete.
If successfully tested and licensed, adjuvants should not bald, scar, or 
poison patients. The reduced side effects should not only increase 
patience response, but may also establish health care standards that
GO “Corporate Profits Surged 33% in 3rd Period, Before Market Crash." 
Wall Street Journal. 9 November 1987, p. 20.
G1 R. Weiss, "Cancer Therapy Risks Assessed," Science News. 12 
September 1987, p. 165.
G2 Joseph Carey, "Fighting Against Cancer." U.S. News and World Report. 
20 August 1984, p. 53.
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more toxic and maiming applications cannot meet.
Infectious disease therapy and prevention trends are also sketchy. 
Although sketchy, the market size is staggering (Ribi has estimated it 
as high as $3 billion annually). Firms pursuing this market follow 
three trends: complementing existing therapies to reduce undesirable
side effects, improving existing therapies to keep pace with ever 
changing viruses, and developing preventative cures for specific 
infectious disease ailments.
Molecularly and genetically engineered adjuvants are gaining 
considerable attention. According to a recent report, "a renewed 
interest in vaccine development has been inspired by the advent of new 
biosynthesis and molecular engineering technologies which offer a new 
range of potentially safe and effective products. Their ability to 
improve the safety profile of existing products and create new vaccine 
products for a host of serious infectious disease has the potential to 
expand the vaccine market at least two-fold to reach $2 billion 
worldwide.
1987 Biotechnology Data Group, "Drug Del ivery/Formulât i o n , Issues 
and Commentary Reports. (Cambridge, Mass.: 1987), p.3.
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CHAPTER VI;
CORPORATE STRATEGY ANALYSIS
The following chapter discussion follows the outline process for 
formulating competitive strategy presented by Michael E. Porter in 
Competitive Strategy (The Free Press, New York: 1980, pp. xix-xx).
A. What Is the Business Doing Now?
1. Assumptions. Virtually all of Rlbl ImmunoChem Research, Inc.'s 
corporate strategy centers on one critical assumption: the Company, or 
Company collaborators, will develop patented federally-approved products 
containing Ribi ImmunoChem adjuvants. It is not certain that Ribi 
ImmunoChem will receive federal approval to distribute products 
containing its adjuvants Growth in the highly competitive 
blopharmaceutical industry could occur in any direction, and not 
necessarily in the direction of (Ribl ImmunoChem*s) molecularly- 
engineered adjuvants.
Although a thorough competitor analysis has not been undertaken, 
the Company perceives itself the world's leader in adjuvant research. 
Certainly Edgar Rlbl and his Company colleagues have contributed 
immensely to the field, but with new competitors entering the industry 
continually, assuming leading competitive advantages is questionable.
2. Mission and strategies. Ribi ImmunoChem Research, Inc. is guided by 
its Board of Director's corporate policies. The policies direct the 
Company's operating, financing, and investing strategies toward
49
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
50
achieving the Board's corporate mlssion--to become a fully integrated 
pharmaceutical company focused primarily on development of adjuvants and 
human health care adjuvant applications.
Ribl ImmunoChem*s competitive strategy is centered on protecting 
its products and technology. The Board believes that an important 
element to Company success is building a strong patent position. By 
patenting its technology and products, the Company is entitled to large 
royalties or licensing fees by any industry researcher who "borrows”
Ribi ImmunoChem discoveries. The more patents Issued, the better 
chances that applications developed by Ribi ImmunoChem will be used by 
other industry researchers.
Long-term Company success centers on marketing human health care 
products. Currently, important malignant and infectious disease 
research is examining applications of Ribi ImmunoChem products and 
Ingredients. If any of the research results are approved for 
distribution, Ribi ImmunoChem should prosper. Accordingly, Company 
management has devised strategies to enhance chances of approval through 
expanded clinical trials and product development efforts.
Expanded clinical trials and product development are expensive. To 
fund Company operations, Ribi ImmunoChem executives have implemented 
financial strategies designed to generate capital to fund operations 
until a Company human health care product is approved for commercial 
distribution. Most of the capital has been raised by issuing common 
stock to the public, investing the proceeds in short-term interest 
bearing securities, and then selling the securities as needed to provide 
operating funds Additional capital has been raised by negotiating
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contract research awards and improving product sales of RIBIGEN®.
Rlbl ImmunoChem Research, Inc. is faced with two problems. First, 
research and development of products worthy of federal approval takes 
years and is expensive. Second, access to particular markets requires 
considerable capital to market and distribute products. In response to 
the problems, Ribi ImmunoChem's Board of Directors has devised three 
marketing/ distribution strategies to offset the Company's deficiencies.
First, in the event that the Company is approved to market a 
product that is prescribed by doctors for patients, Rlbi ImmunoChem will 
market and distribute the product directly to the physicians. This 
strategy will minimize marketing expense and maximize potential profits. 
Cancer treatment applications using DETOX* or OVAMID* to serve multi- 
million dollar markets would follow this marketing/distribution 
strategy.
Second, products approved for distribution which include Company 
adjuvants in combination with a partner’s products will become the 
partner's marketing/distribution responsibility. Commercial rights, 
royalties, and/or licensing fees will compensate Rlbl ImmunoChem. This 
strategy is designed to address the huge market served by vaccines. 
Melanoma treatment developed by Dr. Malcolm Mitchell (University of 
Southern California) using DETOX* would follow this strategy, as would 
other research companies testing Ribi adjuvants In Infectious disease 
vaccines.
Finally, when a major health care company dominates a market 
segment, and if Ribi ImmunoChem Research, Inc. adjuvants enhance the 
major company's products. Ribi ImmunoChem will license its products in
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return for licensing fees and royalties. Currently Baxter Healthcare 
Corporation is researching methods of preventing certain forms of 
infectious disease using MPL^, one of Ribl ImmunoChem s proprietary 
immunostimulants. If Baxter research is successful, Rlbl ImmunoChem
Research, Inc. would receive licensing fees and royalties based on
worldwide distribution of products which could serve multi-million, 
possibly billion dollar markets.
B. What is Happening in the Environment?
1. Industry analysis. Ribi ImmunoChem Research, Inc. operates in a
complex emerging industry. Because contemporary techniques for treating 
or preventing malignant and infectious diseases are unsafe or 
Ineffective, considerable research effort is emerging to counter the 
problems.
Industry competitors of varying size and research applications are 
entered the new generation blopharmaceutical industry. According to 
Kidder and Peabody estimates, "by 1990 approximately a dozen known 
biotechnology competitors will enter the industry with marketable 
products."64 Although specific applications developed by any one of the 
competitors could monopolize certain therapy methods (markets), it is 
unlikely any of the competitors can develop products to serve all of the 
new human cancer and infectious disease health care needs. As a result, 
the industry is fragmented— none of the competitors can command future 
industry leadership.
64 Kidder, Peabody 4 Company, Inc, "Biotechnology Products, 
Competitors, and Market Share Assumptions." Asset Valuation Model. 1986.
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At present, competition within the emerging blopharmaceutical 
industry Is driven by two forces: threats of new entrants, and threats 
of substitute technology/products. As the Industry's competitors
develop newly approved products for market, consumers will be more free
to choose products/treatments for their ailments. Accordingly, 
competitor rivalry will likely Intensify. More effective products at 
affordable prices will become more important considerations to influence 
consumer purchasing decisions
In addition, as the industry grows and offers consumers a broader 
range of product/treatment selection, customer preference will become a 
more significant force. Responding to customer choices, the industry's 
competitors will likely offer Improved service as well.
Current Industry competitors attempt to reduce the immediate 
substitute and entrant threats by obstructing or slowing competitor 
progress. A common strategy pursued by the competitors is to patent all
discoveries. Additionally, the competitors attempt to create
collaborations between institutions, government agencies, or even other 
biotech companies. The collaborations are hoped to effect new advances 
in research and product development— new advances that will benefit the 
collaborators.
2. Competitor analysis. Because Ribi ImmunoChem Research, Inc. is 
competing in an emerging (future) industry where growth could occur in 
many directions, competitor analysis is sketchy. Even though the 
analysis is not exact, it serves a valuable tool in predicting a 
competitor's response to industry change and rivalry.
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Basically, two Interrelated future goals drive the Industry's 
competitors— tremendous profit and market leadership. Competitors are 
racing to improve or develop new technology and products for combatting 
infectious and malignant disease. According to Kidder and Peabody 
estimates (table 5), by the time federal approval is granted Ribi 
ImmunoChem's DETOX* (1988), 84% of the Company's biotechnology 
competitors will emerge with competing cancer products or technology.
Some may be intended to compete directly with DETOX* in specific 
applications, some may not. Ribi ImmunoChem officials downplay the 
substitute threats (of interferon, interleukin, monoclonal antibodies, 
etc.) as less safe and effective than Ribi ImmunoChem Research, Inc. 
products.
The competitor that first develops improved technology or products 
should enjoy tremendous profit and little immediate rivalry. However, 
threats of emerging substitute products or technology pose restrictions 
on how long the leader can hold its position.
As an example. Chiron (biotech competitor) announced in 1987 that 
the company had received federal approval to market a hepatitis B 
vaccine. The vaccine earned Chiron $70 million in 1987. Shortly after 
Chiron's announcement. Smith, Kline and French also announced approval 
to market (in Europe) a substitute vaccine for hepatitis B treatment. 
According to recent annual reports, Ribi ImmunoChem Research, Inc. has 
also identified hepatitis B as a possible market for Company products.
The continual threat of substitute products which could Improve 
conventional hepatitis B therapy, does not assure Chiron will enjoy the 
profit and market leader position forever, nor does it assure Ribl
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ImmunoChem would hold the position long (if Rlbl Introduced an improved 
product).
Although each competitor will differ in how it moves products from 
the laboratory to the consumer, many similarities will also exist.
First, each competitor will need to secure adequate capital to finance 
research and development operations until its products are approved for 
commercial distribution. Second, each competitor will seek product or 
technology protection through aggressive patenting Finally, each 
competitor will seek (or internally develop) access to product 
distribution channels.
The industry is driven by the hope that current malignant and 
infectious disease technology can be improved. Each competitor draws 
favorable conclusions about how effective and safe its product is in 
comparison to the competition. The conclusions often lead to 
unsupported claims of industry leadership. However, from a competitive 
analysis perspective, until the products gain federal approval for 
customer distribution, assuming leadership positioning is premature.
Competitive capabilities vary from company to company, and are 
subject to change. Financial strength, innovation, cost positioning, 
research/administrative ability, government support, historical market 
prominence, and timing all contribute to competitors' strengths and 
weaknesses. Some competitors have distinct advantages at present which 
may not continue into the future industry. To the contrary, some 
competitors may have distinct disadvantages at the moment which may 
change in the future industry. As an example, although a small biotech 
company may lack capital strength to finance operations long enough to
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bring a product to market, possible future acquisitions, partnerships, 
or mergers can (with the signing of an agreement) provide sufficient 
capital backing to strengthen the company's competitiveness.
The greatest competitive advantage in the blopharmaceutical 
industry is getting products to market first. According to Kidder and 
Peabody estimates (Table 5), Amgen, Biogen, and Genentech hold a 
competitive advantage by being the first to introduce alpha-interferon 
treatment. Numerous other cancer treatments have been estimated to 
reach market before Ribi ImmunoChem Research, Inc. products. Kidder and 
Peabody estimate 84% of the competitors should introduce a cancer 
product before Ribi ImmunoChem. Many of the products may not compete in 
the same Company-sought markets however.
A second competitive advantage in the blopharmaceutical industry is 
capturing market share leadership. According to Kidder and Peabody's 
estimates, Ribi ImmunoChem Research, Inc. will enjoy a monopoly over 
markets that seek products containing detoxified endotoxin adjuvants.
Only one other biotech firm can come close to monopolizing specific 
cancer markets— estimates predict Immunex will capture 90% of 
interleukin-1 markets.
Competitors respond to threats of substitution and rivalry 
differently. Offensively, competitors are expected to mount campaigns 
to Improve chances that they will be the first to introduce new 
technology or products. Accordingly, enhanced clinical research and 
product development, and collaborations with private, public, and 
government research operations will continue. Also, forward integration 
into marketing and distribution, scale economy production, and seeking
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new applications for previously developed proprietary technology is 
expected. Defensively, all competitors are expected to continue 
aggressive product and technology patenting.
3. Societal analysis. Changing societal and governmental pressures 
will lead to new opportunities and new threats. With increasing risk of 
life-threatening infections (eg: AIDS) and diseases, society is likely 
to lobby government for enhanced support of industry research and 
product development. Targeted for developing more effective and safer 
substitute technology or products, the support could include expanded 
subsidies and contract research awards. Easing of federal regulation 
may also be sought to rush potentially effective cures to patients 
quicker.
Society is also in need of cheaper infectious and malignant disease 
treatment. Societal pressure to lower treatment costs could lead to 
Improved liability protection of industry competitors.
On the other side of the coin, industry competitors are faced with 
potential looming threats of product recall. If following federal 
approval, a product is later found unsafe or ineffective» the government 
could recall the product.
4. Strength# Ribi ImmunoChem is technologically well-focused, and 
works aggressively toward a concise long-range mission. The Company 
employs the talent of its experienced research and administrative team 
to develop a unique approach (molecularly-engineered adjuvants) to 
treating select malignant and infectious diseases.
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The disease markets pursued by Ribi ImmunoChem are substantial, and 
currently in need of new or improved technology/products. Two products 
are currently undergoing federal human clinical trials, with the first 
product (DETOX^) expected to reach market by 1990 (according to Company 
estimates).
Presently, Ribi ImmunoChem enjoys a strong patent position, and 
has negotiated research agreements with private and public research 
operations to improve chances that a product will be developed which 
uses Ribl ImmunoChem adjuvants. Of major significance, Ribi ImmunoChem 
is availing adjuvants to the University of Southern California, the U S  
Army Medical Command, and Baxter Healthcare Corporation. Each of the 
partners is capable of providing tremendous research support for long 
periods of time.
Although Edgar Ribi's unfortunate death could have limited research 
innovation and direction, it did not. Ribi ImmunoChem's research staff 
is led by scientists who collaborated with or worked under Dr, Ribi's 
direction during his pursuit of refining adjuvant technology. Serving 
as a mentor. Dr. Ribi built a team of competent Company scientists 
experienced in developing molecularly-engineered adjuvants.
Ribl ImmunoChem Research, Inc. is managed by competent leaders as 
well. In particular, under Nils Ribi's presidency, the Company expanded 
operations and grew rapidly through public stock offerings, and 
profitable Investments. Understanding his personal limitations however. 
Nils Ribi requested the Board of Directors to accept his resignation and 
to begin looking for a new president. Dr. Robert Ivy was recruited in 
the summer of 1987. He brought the Company over thirty years of
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experience at moving pharmaceutical products to market.
Rlbi ImmunoChem Research, Inc. Is directed by carefully designed 
financial and marketing/distribution strategies. Aimed at efficiently 
moving products from clinical testing to customers in the shortest time 
possible. Company management has sought methods of financing expanded 
clinical research and product development operations. Proceeds from the 
sale of common stock and cash raised from selling short-term securities 
has provided most of the capital needed. Investment interest income and 
product sales have also contributed to the capital needed to fund 
operations. Debt has been avoided.
The Company has devised marketing/distribution strategies that 
offset customer access drawbacks. The strategies assure that every 
product that reaches federal approval will be moved to the customer in 
the shortest time possible, and with the least expense to the Company.
The Company is diversified into research and animal health care 
products. Although Ribl ImmunoChem is not aggressively pursuing animal 
health care markets (because the markets are extremely competitive), the 
Company does market a federally approved animal cancer product 
(RIBIGEN®). Future Ribi ImmunoChem strategy provides flexibility in 
developing products for animal health care if Company research for human 
health care products discovers an application which fits animal health 
needs.
Finally, Ribi ImmunoChem Research. Inc. is located in Hamilton, 
Montana, Besides providing a less expensive operating environment. 
Hamilton is near other biotechnology research centers; the University of 
Montana, and the Rocky Mountain Laboratory.
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5. Weaknesses. Similar to most companies, Ribi ImmunoChem Research.
Inc. suffers weaknesses. Although the weaknesses are few, any of them 
could place the Company at a serious disadvantage.
First, the Company is adequately capitalized at present, however 
the Firm could run out of cash by 1991. The assessment is depicted in 
Table 4 and is based on the following projections:
— > Rlbi ImmunoChem will triple its labor force over the next five 
years to 150 employees as Nils Ribi and Bob Ivy have 
announced,
— > Product sales will not improve (assuming sales will not improve 
significantly until a new product is approved for commercial 
distribution),
— > stock issuances will yield the same proceeds as 1987,
--> and the Company will continue the recent trend of
liquidating investment securities to fund operations through 
1991 (the point when the pool of securities would run out).
Changes in any one of the assumptions could alter the Company's 
solvency position* However, the changes would need to be dramatic to 
markedly improve the Company's solvency.
Second, the Company's stock prices have fallen drastically. The 
situation places the company in a prime acquisition position for two 
reasons: Rlbi ImmunoChem does not control the majority of stock issued, 
and the Company appears to be moving closer to federal approval of
Theresa Johnson, "Ribi to Help Fund Graduate Research at UM," 
Missoulian, 20 March 1988, pp.1-2.
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products serving huge markets.
Finally, the Company has not completed an in-depth competitor 
analysis to determine the following three concerns: which companies pose 
threats of Introducing competing products; how far the companies are 
along in clinical testing; and how well the companies are capitalized.
C. What Should the Business be Doing? In almost all cases, Ribi 
ImmunoChem Research. Inc. is guided by concise strategies tailored to 
Company strengths and opportunities. However, to reduce competitor 
threat, and advance the Company's opportunity to reach the Board's 
corporate mission (to become a fully integrated pharmaceutical company, 
with primary focus on development and application of adjuvants for human 
health care) Ribl ImmunoChem Research. Inc. is encouraged to consider 
the following recommendations:
1. Conduct a thorough competitor analysis. Until Ribi ImmunoChem 
Research, Inc. can research which competitors pose the most serious 
short and long-term threats, devising an effective competitive strategy 
is difficult. Accordingly, the Company should dedicate resources to 
finding answers to critical questions concerning: what companies pose 
threats of introducing competing products; how far along the companies 
are in clinical testing; and how well (and by what means) the companies 
are capitalized.
2. To supplement cash flows, expand research and development of 
veterinary adjuvant applications. Although Ribi ImmunoChem Research,
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Inc.'S human health care products are moving closer to federal approval, 
the approval may be delayed longer or possibly never granted. According 
to Nils Ribi. approval for human health products takes at least eight 
years. To counter the trend of draining capital reserves to fund 
operations through the long approval process, the Company should expand 
efforts to develop veterinary products that are not subject to similar 
intense clinical testing.
Currently, the Company markets a veterinary product (RIBIGEN®) 
which involved shorter testing and evaluation periods (than products 
intended for human health care). Two years after entering federal 
testing phases, RIBIGEN® was approved for commercial distribution.
Aithough RIBIGEN® markets are not substantial, the product generated 
sales of $160,000 in 1985.
3. Postpone expanding the work force. In March 1988, Nils Ribi 
announced that the Company intended to expand the work force from 50 to 
150 staff members over the next five years. According to projections 
included in table 4, the expansion would lead to total depletion of 
investment securities and cash flows would not cover operating expenses 
in 1991.
Expansion of Rlbi ImmunoChem Research, Inc.'s work force is not 
necessary to move the first products through later clinical testing 
phases. Prior to the expansion notice, the Company had successfully 
operated with adequate staff to move DETOX* and OVAMID* through pre­
cllnlcal and early clinical trials. The staff size should be adequate 
to complete the phase two and three trials of Rlbl ImmunoChem's two
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human health care products.
If expansion were delayed, and sales and stock proceeds remained 
the same, the Company would only need to liquidate $5 million of its 
investment securities to generate adequate cash to cover operating 
expenses in 1991. The move would preserve $5.6 million in security 
investments for years following 1991 if further liquidation becomes 
necessary. (Table 6 illustrates the cash flow situation if the work 
force is not expanded.)
Table 6
RI8I IfHiNOCHW RESeWH, INC 
Pro Form Cash Flow (Revised)
(Thousands)
Cash flows from Operating Jtetivities; 
Net Income (Loss) 
Oepreciation/Amortfzation 
Accouits %ceivab1e 
Accrued Interest Receivable 
Inventories 
Other Current Assets 
Accounts %yeb1e 
Accrued Expenses 
Deferred Income
Net Cash Flows from Operating Activities
Cash Flows from Investing Activities: 
Capital Expenditures 
ftp w ts for Other Assets 
Change in Investment Securities
Net Cash Flows from Investing Activities
Cash Flows from Financing Activities:
Proceeds from Issuance of Stock
Net Increase (Decrease in Cash)
Cash-Beginning of Year
Cash— Bid of Year
1985 1986 1987 1988 1989 1990 1991
(479) 55 (1,086) (1,086) (1,086) (1,086) (1,086)
146 135 147 300 300 300 300
(33) 9 (4) 0 0 0 0
(255) (402) 472 0 0 0 0
41 (34) 17 0 0 0 0
(22) (52) 22 0 0 0 0
(21) (95) 324 0 0 0 0
11 62 , 146 0 0 0 0
6 (6) 0 0 0 0
(612) (316) 32 (786) (786) (786) (786)
(161) (204) (2,175) 0 0 0 0
(102) (49) (96) 0 0 0 0
(10,694) 2,714 425 200 800 800 700
(10,957) 2,461 (1,846) 200 800 800 700
11,115 19 7 7 7 7 7
(454) 2,164 (1,807) (579) 21 21 (79)
727 273 2,437 630 51 72 93
$273 $2,437 $630 $51 $72 $93 $14
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RIBI DffJMOCHEM RESEARCH, INC.
Statement» of Operations 
Years ended Dflnwnber 31, 1987, 1986 and 1985
1987 1986
Revenues:
Sales................................ $ 475,773 474,502
Contract services................  124,136 25,046
License and option fee s..........  92,903 —
Investment inoctne, n e t ..........  866,548 1,106,708
OCher.................................. .... 4.807 4.743
1,564,167 1,610,999
Costs and expenses:
Purchases and production.......... 165,397 103,300
Contract research and development . . . 83,318 18,622
Proprietary roaearch and development . . 1,080,617 788,049
Depreciation and amoritization...  146.751 135.449
2.650.492 1.806.403
less before extraordinary item . . (1,086,325) (195,404)
Extraordinary itan-life insurance proceeds  rr 250.000
Ket earning# (loss).............. Sfl.086.3251 ____
Earning# (loss) per ccmsnn share:
Los# before extraordinary item . . . .  $ (.13) (.02)
Extraordinazy i t e m ..................  .......... =r  &JSÜL
Net earning# (loss) per
^xjimon share.......................................aOL.
1985
370,605
1,225
12,000
595,956
186
979,972
254,594
1,075
591,776
146.090
1.458.519
(478,547)
(478.5471
(.06)
—  f,Qfi
Avtttag# number of share# outstanding . . aittfiiiTa 7.526.917
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RIBI IMMJMOCKEM RESEARCH, INC. 
statenttnts of Operations 
Years ended Deoenber 31, 1984, 1983, and
1984
1982
Revenues:
Sales ..........
contract research 
Interest . . . .  
other ......
Costs and expenses:
Purchases and production..........
Research and development..........
Selling, general and administrative 
Depreciation and anoritization . . . 
Interest..........................
Net loss
loss per g-iiinmn s h a r e ............
Average number of shares outstanding
$ 402,975 
114,100 
396,361
913,463
164,012
431,296
502,025
103,051
 m
1,299,79% 
$0232,2221
1983
206,231
213,434
249,733
669,963
129,452 
249,362 
422,647 
92,285 
 ids
-524,123_(224.231\
1982
175,993
41,536
107,621
 232
325,900
85,635
112,826
289,101
83,523
-47,523618.609
092.7991
3.077.ani: 2.647.Aia
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RIBI HMJNOCHQl RESEARCH, INC. 
Statemtnts of Operations 
Inception, January 9, 1981 to Deoanber 31, 1981
Revenues;
Sales..........................................$ 65,539
Interest....................................  112,481
Other........................................  5,000
Tat^l mevenues ~ " 183.020"
Costs and Expenses:
Salaries ....................................  162,475
Professional f e e s ............................  27,497
Purchases and productif costs..............  18,645
Payroll taxes................................  13,471
Supplies....................................  9,251
Insurance....................................  11,659
Travel......................................  9,437
Telephone....................................  4,209
Interest....................................  23,126
Depreciation and amortization................  30,357
other........................................  33,059
Total costs and exoenses 343.186
Net loss $ (106,166)
Loss per ccmmon share
s r.221
Average number of Aaree outstanding 716,852
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RIBI MtJHOCaEM RESEABŒ, Die.
Balance Sheets
31, 1987 a m  1986
Assets
current assets: 1987
Cash a m  short-term deposits........  «
Investment securities...............   ? 630,644
Accounts receivable . . . . ! ! ! ! ! * * * ’ 10,345,112
Accrued interest receivable . ! ! . 58,312
Inventories....................... ! ! ! ’ ** 264,078
Other current assets............  192,673  127■
T o t l  a s « t , ................  - ll.sia.n»
Property, plant a m  equipment:
Equipnient, furniture a m  fixtures.......... i is, «««.............  i:%S:
o=r-tructlan In p m g r w . ...........! ! ! ! ! 1 i-IS.Sg
Accumulated depreciation....................
Net property, plant a m  equipment . . . .  3,5«*440
Other assets, n e t .................................... 3*^
Total assets  $ is.sea
Current liabilities:
Accounts payable  $ 353,040
Aociuad expenses ............................  235,633
Deferred i n o o a m ............................ ..................
Ittal current liabilities..........
ShareholdscB* equity:
Ptefarred stock, $.10 par, 1 0,000,000 authorized 
shares; none issued a m  outstanding . . . .  __
cessai stocdc, $.001 par, 2 0 ,000,000 authorized 
aharw; 8,622,870 a m  8,620,170 issued a m
oustanding in 1987 a m  1986, respectively . . 8,623
Additional paid-in captital..........  17,463,621
Amailatsd deficit..........................  (2,474,711)
Total Aareholders* e q u i t y ..  1 4.997.533
CcsBittMnts and ocntingsncies:
Tbtal liabilities a m  shareholders' equity
1986
2,437,767 
10,770,519 
54,498 
736,139 
209,424 
 149.416
14.357, 7C-.
873,573
1,011,749
209,728
1.529.473 
 5fi£x522
1.529.473
314.341
29,229
89,424
— 6.354
-i25.007
8,620 
17,456,336 II*388.38̂ 1
_A6.076.S7Q
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RIBI IMUNOCHEM RESEARCH, INC.
Balance Sheets 
Deoanber 31, 1985 and 1984
1985
   assetscurrent assets:
;  * "'75,.,07
Accrued interest receivable.......... i ........
Inventories............................   .
Other current assets...............  ......................   22x532
Total current assets.................  14,429,186
Property, plant and equipment
Equipment, furniture, fixtures and vehicles . . . .  aru
............................................
^ ................................................  a w z 9
Aocunjlatad daçraelatlen.........................
Met property, plant and e c ^ p n e n t ...........  Î T Î S ^ m
Other assets, n o t ..................................  269.847Total assets $ KLi5a!a,x
T.<*blHttes and RmltY
current liabilities:
Acsoounts payable................................. 124,619
Aocrusd expenses.................................  32x124
Total current liabilities...........  151.743
ShartfibLdsrs* e q jltyO a a m  stock, $.001 par; 10,000,000 authorized shares;
8,614,670 and 6,899,800 issued and outstanding in
1985 and 1984, respectively...................  8,615
Additional paid-in capital.......................  17,437,448
Cosmen stock w a rra n ts ......................................................... —
Axnwilatsd d ef i c i t ............................. f1.442.982%
Total shareholders' etjiity...........  l6.003.o8i
ocBBdtaaRtsTbtal liabilities and shareholders' e g i i ^ .........$
1984
3,517,371 
30,304 
78,815 
216,574  75,0%
3,918,159
679,093 
975,665 
—  84,9221,739,578
 301.850
1,437,728
171,794
145,585-15.737
iSix312
6,898
6,323,794112
-(064.435%
_5J)56,342
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Balano0 ShMts 
n#nmmh#r 31, 1983 and 1982
70
II I 1983
Qirrent aaaetat
Cash and money market deposits, irciudiro 
U.S. Treasury bills of $953,084 atDecember 31, 1983   . . ___Accounts receivable...................• • . . . ^ 2,653,204
Inventories........................ ! * ’ * * *
Laboratory supplies and other............  ! ! !
Total current a s s e t s .............  2 .9is.^n^
Property and equipment, at cost:
Equipment, furniture, fixtures and vehicles . . .  5*75
..........................................
.................................... _â2*25fl
Accumulated depreciation.....................
Net prcperty and equipment..........  aai .îT^
Other assets, n e t ................................. _  80.05a
Total a s s e t s ...................... $ a^a77.n5a
Accounts p ayable.............................  16,848
Accrued eagenses .............................  12,015Deferred revenue.............................
Total current liabilities.........
stockholders* equity (note 4):
CcsBon stock, $.001 par; 10,000,000 (5,000,000 in 
1982) authorised ahares; 3,109,500 and 2,982,500 
and outstanding in 1983 and 1982,
respectively.................................  3,109
Additional paid^capital.......................  4,502,937
OoBBon stock %mzzants.........................  237
Accunulated def i c i t ...........................
Total stockholders’ e q u i ^ .........
OoamitisentsTotal liabilities and stockholders' equity . .$ g+gzjgg
1982
3,061,97414,351
150,41228,102
3.254 a?*
443,670 
339,268 
— a3.?5Q 866,688 
— 198.19?0
__756.738
4.034.749
54,878
12,261
2,9824,365,187
17,800
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RIBI DMJNOŒEM RESEARCH, INC.
Balance Sheet 
December 31, 1981 
Aseetscurrent Assets:
cash, including certificates of deposit of $460,000 ........ si qqo
Accounts receivable.........................................\  lo'etl
Inventories....................................................  62 753laboratory supplies............................................  17'458
Other  ...................................................  26!fl2fi
Ibtal current assets 1.20*
property and Bqaipnent, at Cost:
Bcjjdpnent, furniture and fixtures and vehicles.................  389,323
Buildings.................................................... 347*955
Land .  .................................................. __ - 62.700
770.869
Other Assets, at Cost, less Applicable Amortization 4,993
Total assets S 1.984 ,122
r.l^tltties W  Eouitv
Current Liabilities:
Notes payable................................................ $ 453,757Accounts payable............................................  12,957
Accrued expanses ....................................   -19.442
Total current liabilities 486. is6
par; authorized 5,000,000 shares; issued and
outstaniing 872,000 shares................................  872
jy&ütionel paid-in capital..................................  1,657,260
— warrants...........   300Déficit accumulated during develqpsant stage.................  —
Ttotal stockholders* etjaity..................  1.498.266
“ “ÎSSfîlabUitlss and stockholders* equity Li.Mi,4M
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